Related Experiment Video

Updated: May 21, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

[Vaccination of cystic fibrosis patients]

L Iordache1, J Gaudelus, D Hubert

  • 1Université Paris Descartes, Inserm CIC BT505, Centre d'Investigation Clinique de Vaccinologie Cochin-Pasteur, Hôpital Cochin, AP-HP, Paris, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|June 12, 2012
PubMed

Insights

Vaccination guidelines for cystic fibrosis patients include standard and specific vaccines like influenza and Pneumococcus. Further research on vaccine efficacy and new respiratory infection vaccines is crucial for patient care.

Area of Science:

  • Immunology
  • Pulmonology
  • Infectious Diseases

Context:

  • Cystic fibrosis (CF) patients require specific vaccination strategies beyond the standard schedule.
  • Recommendations cover influenza, Pneumococcus, viral hepatitis A and B, and varicella.
  • Live attenuated vaccines are permissible pre-transplantation.

Purpose:

  • To outline current vaccination guidelines for individuals with cystic fibrosis.
  • To highlight areas needing further clinical investigation regarding vaccine efficacy.
  • To identify the need for novel vaccines targeting common respiratory pathogens in CF.

Summary:

  • Current CF vaccination guidelines integrate standard schedules with specific recommendations for influenza, Pneumococcus, hepatitis A/B, and varicella.
  • Live attenuated vaccines can be administered before lung transplantation.
  • There is a critical need for clinical studies assessing vaccine effectiveness in CF patients.
  • Developing new vaccines against Staphylococcus aureus, Pseudomonas aeruginosa, and RSV is a significant challenge.

Impact:

  • Optimizing vaccination protocols can improve health outcomes for cystic fibrosis patients.
  • Further research will refine vaccine strategies and potentially reduce infection-related morbidity.
  • The development of new vaccines addresses key pathogens contributing to respiratory decline in CF.

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Vaccinations01:51

Vaccinations

Overview
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...